United States v. Jazzmon Russell

Court of Appeals for the Ninth Circuit·Decided September 5, 2024·No. 22-50056·Unpublished

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS SEP 5 2024 MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA, No. 22-50056

Plaintiff-Appellee, D.C. No.

2:17-cr-00533-RGK-1

v.

JAZZMON UNIQUE RUSSELL, AKA MEMORANDUM* Jasmine Russell, AKA Jazzman Unique Russell,

Defendant-Appellant.

Appeal from the United States District Court for the Central District of California R. Gary Klausner, District Judge, Presiding

Argued and Submitted July 15, 2024 Pasadena, California

Before: PAEZ and SANCHEZ, Circuit Judges, and LYNN,** District Judge.

Jazzmon Russell (“Russell”) appeals his conviction under 18 U.S.C.

§ 922(g)(1) and his statutory maximum sentence. We have jurisdiction under 28 U.S.C. § 1291 and 18 U.S.C. § 3742. For the reasons explained below, we vacate

*

This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3.

**

The Honorable Barbara M. G. Lynn, United States District Judge for the Northern District of Texas, sitting by designation.

the judgment and sentence and remand for the district court to make a reliability determination as to the DNA evidence and expert testimony.

Russell raises several challenges to his conviction and sentence. He alleges the following errors: (1) admission of the DNA evidence and expert testimony without a reliability finding; (2) admission of the 911 and dispatch calls; (3) admission of subsequent act evidence; (4) an impermissibly coercive Allen charge; (5) insufficient evidence to support his conviction; (6) cumulative error; (7) denials of his motions to continue the trial and replace counsel; and (8) procedural and substantive errors in sentencing him to the statutory maximum. We address each challenge in turn.

1. Russell challenges the district court’s admission of DNA evidence and expert testimony under Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993) and Federal Rule of Evidence 702. We review a district court’s decision to admit evidence and expert testimony for abuse of discretion. United States v. Cox, 963 F.3d 915, 924 (9th Cir. 2020); United States v. Ruvalcaba-Garcia, 923 F.3d 1183, 1188 (9th Cir. 2019).1 The district court erred by failing to make an “explicit reliability finding”—

1 Russell objected to the DNA evidence and sought to exclude it in a pre-trial motion in limine, and the district court denied the motion without explanation. Thus, Russell fairly preserved his objection for appeal. See Tan Lam v. City of Los Banos, 976 F.3d 986, 1005 (9th Cir. 2020).

as required by Daubert—before admitting the DNA evidence and expert testimony. See Ruvalcaba-Garcia, 923 F.3d at 1190 (quoting United States v. Jawara, 474 F.3d 565, 583 (9th Cir. 2007)). The district court denied Russell’s motion in limine seeking to exclude the DNA evidence without explanation, and the court’s only statement regarding the expert testimony was that the expert “qualifies.” Qualifying an expert without finding their proposed testimony reliable does not satisfy Daubert. United States v. Valencia-Lopez, 971 F.3d 891, 899 (9th Cir. 2020). The district court thus abused its discretion by failing to make an express reliability determination. Ruvalcaba-Garcia, 923 F.3d at 1189–90.

The district court’s error was not harmless. To establish harmlessness, the government must show either (1) that the admitted expert testimony was relevant and reliable based on the record or (2) that it is more likely than not that the jury would have reached the same verdict even if the expert testimony had been excluded. See id. at 1190. The government has not made either showing here.

We cannot conclude from the trial record that the DNA evidence and expert testimony is reliable. See id. at 1190. The DNA expert testified about her use of STRmix, a probabilistic genotyping software, to analyze the DNA evidence in Russell’s case. But the record raises questions about the reliability of this methodology and its application here. For instance, Russell’s motion in limine cited to a 2021 report from the National Institute of Standards and Technology

(“NIST”), which concludes that “there is not enough publicly available data to enable an external and independent assessment of the degree of reliability of DNA mixture interpretation practices, including the use of probabilistic genotyping software (PGS) systems” like STRmix. National Institute of Standards and Technology, DNA Mixture Interpretation: A NIST Scientific Foundation Review, at 6, 75 (June 2021) [hereinafter NIST Report], https://doi.org/10.6028/NIST.IR.8351-draft. 2 The NIST report highlights the lack of “established and accepted criteria for reliability with complex mixtures involving contributors containing low quantities of DNA template.” Id. at 82.

The report also discusses how the number of assumed contributors, the percentage of the suspect’s contribution, and the amount of DNA at issue can affect the reliability of probabilistic genotyping for complex samples. Id. at 5–6, 20, 30–31, 75. These factors are critical to assessing whether the methodology was reliably applied in a given case, as required by Federal Rule of Evidence 702. See Fed. R. Evid. 702(d) (indicating that an expert’s opinion should reflect “a reliable application of the principles and methods to the facts of the case”); Daubert, 509 U.S. at 593 (holding that the district court should assess “whether that reasoning or methodology properly can be applied to the facts in issue”).

2 The NIST, an agency of the U.S. Department of Commerce, conducts studies to review the scientific bases of forensic methods. See NIST Report, at ii.

The DNA samples in Russell’s case involved three- and four-person mixtures and low quantities of DNA. The record does not contain information about the percentage of Russell’s assumed contribution to the DNA samples. Nor is the exact amount of DNA in the samples fleshed out in the record. In fact, the record implies that only one of the samples contained the amount of DNA that the expert would typically use. Additionally, it is not clear whether STRmix had been properly validated for use with three- and four-person mixtures containing the miniscule amounts of DNA at issue here.3 The record suggests that the expert’s lab had performed a validation study for up to three-person mixtures, but one of the samples at issue had four assumed contributors. Accordingly, the record does not establish that STRmix was reliably applied in this case.

Nor can we conclude that admission of this evidence was otherwise harmless given other evidence against Russell. See Ruvalcaba-Garcia, 923 F.3d at 1190–91 (discussing harmless error). The DNA testimony was a critical piece of evidence in the government’s case against Russell. The government stressed this evidence

3 A lack of proper validation may render DNA evidence unreliable. See e.g., United States v. Williams, 382 F. Supp. 3d 928, 929, 936–38 (N.D. Cal. 2019) (granting motion to exclude DNA evidence analyzed by probabilistic genotyping program due to questions about the number of assumed contributors, the lab’s lack of validation for a higher number of contributors, and the amount of DNA); see also United States v. Ortiz, No. 21-CR-2503-GPC, 2024 WL 2889873, at *4–10 (S.D. Cal. June 10, 2024) (granting motion to exclude DNA evidence analyzed by STRmix due to concerns over the number of assumed contributors and the lab’s lack of validation for a higher number of contributors).

repeatedly during closing argument, and acknowledged before this court that it was a “key piece[] of evidence.”

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Jazzmon Russell, (9th Cir. 2024).

United States v. Jazzmon Russell (United States v. Jazzmon Russell) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Nevils
598 F.3d 1158 (Ninth Circuit, 2010)
McDaniel v. Brown
558 U.S. 120 (Supreme Court, 2010)
Morris v. Slappy
461 U.S. 1 (Supreme Court, 1983)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Crawford v. Washington
541 U.S. 36 (Supreme Court, 2004)
Davis v. Washington
547 U.S. 813 (Supreme Court, 2006)
United States v. Ralph Collins Cawley
630 F.2d 1345 (Ninth Circuit, 1980)
United States v. Waknine
543 F.3d 546 (Ninth Circuit, 2008)
United States v. Cherer
513 F.3d 1150 (Ninth Circuit, 2008)
United States v. Reyes-Bosque
596 F.3d 1017 (Ninth Circuit, 2010)
United States v. Hammons
558 F.3d 1100 (Ninth Circuit, 2009)
United States v. Alfonso Torres
794 F.3d 1053 (Ninth Circuit, 2015)
United States v. James Lloyd
807 F.3d 1128 (Ninth Circuit, 2015)
United States v. Christopher Preston
873 F.3d 829 (Ninth Circuit, 2017)
United States v. Mario Ruvalcaba-Garcia
923 F.3d 1183 (Ninth Circuit, 2019)